A daily pill just doubled survival time for advanced pancreatic cancer — 2026-06-03

## Short Segments Kruger National Park marks a century of wildlife conservation, a milestone celebrated by South African authorities and nature enthusiasts alike. Meanwhile, a critically endangered lemur couple welcomes triplets at a Georgia theme park, showcasing the success of captive breeding programs. In education, schools are giving children a say in their governance, fostering a new wave of student empowerment. And coming up, we'll explore how a daily pill is doubling survival time for advanced pancreatic cancer patients. Kruger National Park celebrates 100 years of protecting African wildlife. On Sunday, South Africa's Kruger National Park celebrated its centenary, marking a hundred years of dedicated conservation efforts. The park, spanning 7,500 square miles, is a cornerstone of the nation's environmental preservation. Celebrations took place at Skukuza Rest Camp, with Minister of Forestry, Fisheries, and the Environment Willie Aucamp expressing pride in the park's achievements. The centenary highlights the park's role as a major tourist destination and a vital habitat for diverse wildlife. As South Africa reflects on this milestone, the focus remains on preserving its natural heritage for future generations. Critically endangered red ruffed lemur triplets born at Wild Georgia Theme Park. In Valdosta, Georgia, a pair of critically endangered red ruffed lemurs has welcomed triplets at Wild Adventures Theme Park. This marks the third consecutive year the resident female has given birth, underscoring the effectiveness of captive breeding programs. The newborns, named Taylor, Red, and Majorie, are a significant addition to the species, which is listed as critically endangered by the International Union for Conservation of Nature. The successful birth offers hope for the future of these lemurs, as conservationists continue efforts to boost their population. Schools are giving children a say in how they are run. In a shift towards inclusive education, some schools are empowering students by giving them a voice in school governance. At Sands School in Ashburton, students have an equal say in decision-making alongside staff. This approach fosters a sense of responsibility and engagement among students, encouraging them to participate actively in their education. Similarly, St Barnabas and St Philip's Church of England Primary in London has improved its Ofsted rating by incorporating student feedback into its operations. These initiatives highlight a growing trend towards democratic education, where students are seen as partners in their learning journey. Young entrepreneurs are flocking to Britain's old-school markets. With traditional job opportunities dwindling, young entrepreneurs in the U.K. are turning to market stalls as a platform for innovation. Thanks to a scheme by the National Market Traders Association, individuals aged 16 to 30 can access free market stalls, transforming these spaces into vibrant business incubators. Young traders are using the markets as live R&D labs, testing products and receiving real-time feedback. This trend is revitalizing Britain's market culture, offering a creative alternative for those less suited to conventional workplaces and fostering a new generation of business leaders. ## Feature Story A daily pill just doubled survival time for advanced pancreatic cancer patients. In a groundbreaking development, a daily pill called daraxonrasib has nearly doubled the survival time for patients with advanced pancreatic cancer. Presented at the American Society of Clinical Oncology's annual meeting, the trial involved 500 patients and showed that those taking daraxonrasib lived an average of 13.2 months, compared to 6.6 months for those on standard chemotherapy. This advancement is particularly significant given the high mortality rate of pancreatic cancer, which has seen little progress in treatment over the decades. The key to daraxonrasib's success lies in its ability to target the KRAS gene mutation, present in over 90% of pancreatic cancer cases. This mutation causes cells to continue dividing uncontrollably, but daraxonrasib effectively shuts off this signal, preventing the cancer from spreading. The drug's development marks a major breakthrough after decades of research deemed the KRAS gene undruggable due to its lack of an obvious binding site for drug molecules. Oncologists have hailed the trial results as unprecedented, offering new hope for patients who previously faced limited options. While not a cure, daraxonrasib represents a significant step forward in managing a disease with one of the highest mortality rates among major cancers. As the medical community absorbs these findings, the focus will be on further research and potential approval for wider use, potentially changing the standard of care for pancreatic cancer patients worldwide.